BeijngFH Health Cohort Study
FHCS
Risk Prediction System for Metabolic Associated Fatty Liver Disease, a Community-based Cohort Study
1 other identifier
observational
8,103
1 country
1
Brief Summary
Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 18, 2022
CompletedFirst Submitted
Initial submission to the registry
September 15, 2022
CompletedFirst Posted
Study publicly available on registry
September 19, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 18, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 18, 2032
September 21, 2022
September 1, 2022
10 years
September 15, 2022
September 18, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cardiovascular disease
Incidence of cardiovascular disease during follow-ups
1 to 10 years
Secondary Outcomes (5)
Malignancy
1 to 10 years
Liver cirrhosis
1 to 10 years
Liver decompensation
1 to 10 years
Liver transplantation
1 to 10 years
All-cause mortality
1 to 10 years
Eligibility Criteria
The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital from April 2022.
You may qualify if:
- Aged 18 years or older
- Permanent residents in Beijing
- Signing informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Beijing Friendship Hospitallead
- Chinese Academy of Medical Sciencescollaborator
Study Sites (1)
Beijing Friendship Hospital, Capital Medical University
Beijing, 100050, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 15, 2022
First Posted
September 19, 2022
Study Start
April 18, 2022
Primary Completion (Estimated)
April 18, 2032
Study Completion (Estimated)
April 18, 2032
Last Updated
September 21, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share